CorrespondenceUpdosing of secukinumab to every 2 weeks results in superior efficacy in patients with severe psoriasis weighing 90 kg or more: a real-world prospective observational study.

McGuire, Niamh; Elamin, Shahd; Gough, Pamela; Cooke, Nicola; McGrath, Conor; McKenna, Kevin; O'Kane, Donal

McGuire, Niamh; Elamin, Shahd; Gough, Pamela; Cooke, Nicola; McGrath, Conor; McKenna, Kevin; O'Kane, Donal.

Afiliação

McGuire N; Department of Dermatology, Southern Health and Social Care Trust, Portadown, Northern Ireland.
Elamin S; Department of Dermatology, Belfast Health and Social Care Trust, Belfast, Northern Ireland.
Gough P; Department of Dermatology, South Eastern Health and Social Care Trust, Dundonald, Northern Ireland.
Cooke N; Department of Dermatology, South Eastern Health and Social Care Trust, Dundonald, Northern Ireland.
McGrath C; Department of Dermatology, Southern Health and Social Care Trust, Portadown, Northern Ireland.
McKenna K; Department of Dermatology, Belfast Health and Social Care Trust, Belfast, Northern Ireland.
O'Kane D; Department of Dermatology, Belfast Health and Social Care Trust, Belfast, Northern Ireland.

Clin Exp Dermatol ; 48(7): 793-812, 2023 07 07.

Article em En | MEDLINE | ID: mdl-36755389

Assuntos

Anticorpos Monoclonais Humanizados; Psoríase; Humanos; Anticorpos Monoclonais Humanizados/uso terapêutico; Psoríase/tratamento farmacológico; Estudos Prospectivos; Resultado do Tratamento; Índice de Gravidade de Doença; Método Duplo-Cego

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psoríase / Anticorpos Monoclonais Humanizados Tipo de estudo: Clinical_trials / Observational_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google